DOI:

At the dawning of interventional cardiology: Andreas Gruentzig, 30 years after <br /> 15 September 1977-15 September 2007

Patrick W. Serruys, Editor-in-Chief

Dear Colleagues,

On the 15th of September 1977, Andreas Gruentzig performed his first angioplasty. Thirty years later, on the 15th of September 2007, three hundred senior interventional cardiologists gathered in that same auditorium where Andreas broadcast live case demonstrations from the cath lab of the University Hospital in Zurich, Switzerland in 1978, 1979 and 1980.

All of us who attended this meeting were profoundly moved to be once again sitting here, on the same seats where we witnessed those live cases in 1978-1980. All of us experienced the same feeling of déjà vu, suddenly appreciating what has been achieved in since. And all of us could see, individually and with deep emotion, our careers passing before us in the blink of an eye, as if those intervening 30 years were nothing more than mere months and not decades. But time does indeed move on, and among those present there were some already enjoying retirement, while the rest of us will soon follow.

When you consider that there are 7.5 million individual patients who have been treated today with drug eluting stents – not even counting all those treated in earlier years by bare metal stents – you begin to understand the depth and lasting impact that this visionary master has had on the personal life of so many. Without any doubt, if Andreas Gruentzig were alive today, he would have been eligible for the Nobel Prize and join fellow giants of cardiology like André Frédéric Cournand, Werner Forssmann or Dickinson W. Richards.

Returning to this 30th anniversary meeting, the attendees were reminded of the luck that must be on your side as an operator, particularly in treating your first case. Adolph Bachmann was a heavy smoker, he spent many days in the CCU with unstable angina before stabilising. During his exercise tests before his treatment, ST elevations were present. Three days after the then successful procedure he still had some residual ST elevation during exercise testing. For some of us, it was the first time we learned about these facts and we were frankly flabbergasted by the luck of patient and operator. And so it is like this that history was written...

Many of us deplored the fact that young interventional cardiologists could not be there with us, participating as well in these two days of presentation and history which reflected the dedication and commitment, but above all the courage, of this first generation of interventional cardiologists.

The sense of comradeship during the two days was overwhelming. The presence of Andreas’s first wife and daughter, as well as so many pioneers of our craft, was exciting, touching and simply breathtaking. This meeting, broadcast on the internet, should be a source of inspiration for the young generation since it’s a complete mixture of ideas, convictions, innovation, linked to an unfailing stubbornness in pursing goals, a sure courage in approaching an infirm fellow man, and the honesty to report acute and late failures. From the very beginning ethics and credibility have been at very the core of this, our endeavour and should always remain there, today and into the future.

Volume 3 Number 3
Nov 20, 2007
Volume 3 Number 3
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00648 Jul 20, 2026
When less is no longer more: very early aspirin discontinuation after ACS
Piccolo R and Vitale A
free

Editorial

10.4244/EIJ-E-26-00010 Jul 20, 2026
Aspirin withdrawal after primary PCI for STEMI: timing matters
Paradies V and Mancini G
free

Editorial

10.4244/EIJ-D-26-00715 Jul 20, 2026
Endotype-guided management of ANOCA: are we ready?
Montone R
free

Original Research

10.4244/EIJ-D-26-00148 Jul 20, 2026
Endotype-guided medical therapy and symptom response in ANOCA
Farina J et al

Research Correspondence

10.4244/EIJ-D-25-01215 Jul 20, 2026
Prevalence of vasomotor dysfunction in patients with residual or recurrent angina after percutaneous coronary intervention
Crooijmans C et al

Flashlight

10.4244/EIJ-D-25-00731 Jul 20, 2026
Collapse of a new-generation magnesium scaffold
Bastante T et al
Trending articles
335.05

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
49.35

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
45.65

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.9

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved